ArticleJournal of clinical neurology (Seoul, Korea)2011
Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy.
Article in Journal of clinical neurology (Seoul, Korea), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- First-year Experience with Brivaracetam in Japan: Real-world Data from Juntendo Epilepsy Center.Neurologia medico-chirurgica · 2026Article
- Article
- Navigating the depths: A comprehensive narrative review on depression in people with epilepsy.Heliyon · 2025Review
- Lamotrigine Drug Interactions: Ignorance is not Bliss.Kansas journal of medicine · 2022Article
- Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218.Translational psychiatry · 2020Article
- Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy.Neuropsychiatric disease and treatment · 2020Article
- Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience.Therapeutic advances in neurological disorders · 2019Review
- Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel.Behavioural neurology · 2018Review
- Investigation of altered microstructure in patients with drug refractory epilepsy using diffusion tensor imaging.Neuroradiology · 2017Article
- Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review.Pharmacological reviews · 2016Review
- Changes in background electroencephalography and regional cerebral glucose metabolism in focal epilepsy patients after 1-month administration of levetiracetam.Neuropsychiatric disease and treatment · 2015Article
- Levetiracetam-induced rage and suicidality: Two case reports and review of literature.Epilepsy & behavior case reports · 2015Article
- The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis.Iranian journal of public health · 2014Article
- Depression and anxiety in people with epilepsy.Journal of clinical neurology (Seoul, Korea) · 2014Review
- Apparent dose-dependent levetiracetam-induced de novo major depression with suicidal behavior.Epilepsy & behavior case reports · 2013Article
- [Guidelines for the management of adverse effects of anti-seizure medications (2023)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeLevetiracetam (LEV) is a new antiepileptic drug that has been found to be effective as an adjunctive therapy for uncontrolled partial seizures. However, the results of several studies suggested that LEV has negative psychotropic effects, including irritability, aggressiveness, suicidality, and mood disorders. We investigated the impact of adjunctive LEV on psychiatric symptoms and quality of life (QOL) in patients with drug-refractory epilepsy (DRE) and determined the risk factors provoking psychiatric adverse events.
methodsA 24-week, prospective, open-label study was conducted. At enrollment, we interviewed patients and reviewed their medical charts to collect demographic and clinical information. They were asked to complete self-report health questionnaires designed to measure various psychiatric symptoms and QOL at enrollment and 24 weeks later.
resultsSeventy-one patients were included in the study, 12 patients (16.9%) of whom discontinued LEV therapy due to serious adverse events including suicidality. The risk factor for premature withdrawal was a previous history of psychiatric diseases (odds ratio 4.59; 95% confidence interval, 1.22-17.32). LEV intake resulted in significant improvements in Beck Anxiety Inventory score (p<0.01) and some domains of the Symptom Checklist-90-Revised, such as somatization (p<0.05), obsessive-compulsiveness (p<0.05), depression (p<0.05), and anxiety (p<0.05). These improvements were not related to the occurrence of seizure freedom. The Quality of Life in Epilepsy Inventory-31 overall score and subscale scores, such as seizure worry (p<0.01), overall QOL (p<0.05), emotional well-being (p<0.05), energy-fatigue (p<0.05), and social function (p<0.05), also improved.
conclusionsAdjunctive LEV in patients with DRE is likely to improve psychiatric symptoms and QOL. Clinicians should be well aware of the psychiatric histories of patients to prevent them from developing serious adverse events related to LEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.